Radiation oncology • radiation biology • biomarkers for radiation toxicities • molecular mechanisms of targeted therapies
My research focuses on the optimization of radiotherapy treatment delivery using advanced technology, the identification of surrogate blood-based biomarkers for radiation toxicity prediction, and the molecular characterization and mechanism of action of novel targeted therapies, such as combi-molecules in high grade glioma and triple negative breast cancer. My research on brain tumors aims to investigate the role of MGMT in invasion/proliferation dichotomy. In breast cancer, the focus is on molecular subtyping triple negative breast cancer and developing a protein signature to predict the risk of locoregional relapse and distant metastasis. I am also working on a comprehensive program to study the effects of radiation on lung fibrosis, cancer invasion and metastasis. I am currently leading an active translational research program to develop new protocols for the treatment of cancer with combined modality ‘radiation and targeted agents', which includes both basic and clinical research.
Olivier Graesslin, Bassam Abdulkarim, Charles Coutant, Florence Huguet, Zsolt Gabos, Limin Hsu1, Olivier Marpeau, Serge Uzan, Lajos Pusztai1, Eric A. Strom, Gabriel N. Hortobagyi, Roman Rouzier, and Nuhad K. Ibrahim. Nomogram to Predict Subsequent Brain Metastasis in Patients with Metastatic Breast Cancer. Journal of Clinical Oncology. 2010 Apr 20;28(12):2032-7.
Bassam Abdulkarim, Julie Cuartero, John Hanson, Jean Deschenes, David Lesniak and Siham Sabri. Increased Risk of Locoregional Recurrence for Women with T1-2N0 Triple Negative Breast Cancer Treated with Modified Radical Mastectomy Without Adjuvant Radiation Therapy Compared With Breast-Conserving Therapy. Journal of Clinical Oncology, 2011 Jul 20; 29(21): 2852-8. (Impact factor 2010: 18.970)
Lisa. Capelle, M. McKenzie, K. Joseph, N.Pervez, K. Tankel, Z. Gabos, J. Amanie, S. Chafe, Bassam. Abdulkarim. Skin Sparing Helical Tomotherapy versus 3D Conformal Radiotherapy for Adjuvant Breast Radiotherapy – a Randomized Controlled Trial. Preliminary analysis of 90 patients. Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e583-90.
Jastaniyah, D.M. Le, N. Pervez, W. Roa, A. Murtha, S. Patel, M. Mackenzie, D. Fulton, C. Field, G. Fallone, Bassam. Abdulkarim. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. Radiat Oncol. 2013 Feb 20;8(1):38. [Epub ahead of print]
David Lesniak, Yaoxian Xu, Siham Sabri, Bassam Abdulkarim. "Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer. PLoS One. 2013 Aug 26;8(8):e71987.